Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Income from Continuing Operations (2019 - 2025)

aTYR PHARMA's Income from Continuing Operations history spans 7 years, with the latest figure at 14796000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 6.47% year-over-year to 14796000.0; the TTM value through Dec 2025 reached 77627000.0, down 14.3%, while the annual FY2025 figure was 77627000.0, 14.3% down from the prior year.
  • Income from Continuing Operations reached 14796000.0 in Q4 2025 per ATYR's latest filing, up from 26745000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 7202000.0 in Q1 2021 to a low of 26745000.0 in Q3 2025.
  • Average Income from Continuing Operations over 5 years is 14043950.0, with a median of 13525000.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: crashed 487.41% in 2021, then grew 7.99% in 2022.
  • A 5-year view of Income from Continuing Operations shows it stood at 8640000.0 in 2021, then grew by 7.99% to 7950000.0 in 2022, then tumbled by 100.74% to 15959000.0 in 2023, then rose by 0.87% to 15820000.0 in 2024, then rose by 6.47% to 14796000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATYR's Income from Continuing Operations are 14796000.0 (Q4 2025), 26745000.0 (Q3 2025), and 20313000.0 (Q2 2025).